Stocks · News reference
Nextcure Transforms Into Avere as Investors Back Oral Psoriasis Therapy
NextCure will merge with Avere in a $320 million exchange to advance oral IL-23 therapy AVR-001 and list the combined company as AVRX.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out
NextCure Q2 EPS $(2.80) Misses $(1.94) Estimate
NextCure (NASDAQ:NXTC) reported quarterly losses of $(2.80) per share which missed the analyst consensus estimate of $(1.94) by 45.08 percent. This is a 75.2 percent increase over losses of $(11.29) per share from the
Why Aehr Test Systems Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of Aehr Test Systems (NASDAQ: AEHR) jumped 29.6% to $93.30 in pre-market trading. Aehr Test Systems beats Q4 estimates and issues FY27 guidance above estimates.